Cargando…

Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway

Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy globally and the third leading cause of cancer-related death. Chemotherapy is one of the main methods in treating HCC, while recent studies have found that the resistance of HCC to chemotherapeutic drugs reduces the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Han, Jin, Zhengkang, Qian, Tao, Xu, Xiaoyong, Zhu, Xiang, Fei, Qiang, Yang, Jiamei, Sui, Chengjun, Xu, Minhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138572/
https://www.ncbi.nlm.nih.gov/pubmed/34025420
http://dx.doi.org/10.3389/fphar.2021.656697
_version_ 1783695837046505472
author Hong, Han
Jin, Zhengkang
Qian, Tao
Xu, Xiaoyong
Zhu, Xiang
Fei, Qiang
Yang, Jiamei
Sui, Chengjun
Xu, Minhui
author_facet Hong, Han
Jin, Zhengkang
Qian, Tao
Xu, Xiaoyong
Zhu, Xiang
Fei, Qiang
Yang, Jiamei
Sui, Chengjun
Xu, Minhui
author_sort Hong, Han
collection PubMed
description Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy globally and the third leading cause of cancer-related death. Chemotherapy is one of the main methods in treating HCC, while recent studies have found that the resistance of HCC to chemotherapeutic drugs reduces the efficacy of the chemotherapy. Falcarindiol (FAD) is a cytotoxic and anti-inflammatory polyacetylenic oxylipin found in food plants of the carrot family (Apiaceae), while its role in HCC remains to be explored. Here, HCC cells (Huh7 and LM3) were treated with FAD at different doses. Cell proliferation was tested by the cell counting kit-8 (CCK-8) method and colony formation assay, while the apoptosis was monitored by flow cytometry. The profiles of apoptosis-related proteins (Bax, bcl2, and Caspase-3), DNA repair proteins (Rad51, BRCA1, and MDC1), and the signal transducer and activator of transcription 3 (STAT3)/Pituitary Tumor Transforming Gene 1 (PTTG1) were verified by western blot (WB) or quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The interaction between STAT3 and PTTG1 was verified by immunoprecipitation (IP). In addition, a xenograft tumor model was constructed in mice to explore the anti-tumor effects of FAD in vivo, and immunohistochemistry (IHC) was performed to count the number of Ki67-stained cells. As a result, FAD inhibited HCC cell proliferation and DNA repair, facilitated their apoptosis, and also enhanced cisplatin (DDP) chemosensitivity. The Combination Index (CI) evaluation showed that FAD and DDP had synergistic effects in repressing HCC cell proliferation. Besides, FAD dampened the STAT3/PTTG1 pathway expression. Further studies revealed that inhibiting STAT3 enhanced the inhibitive effect of FAD on HCC cells, whereas overexpressing PTTG1 attenuated the anti-tumor effect of FAD. Overall, our study illustrated that FAD is a potential anticancer drug and strengthens the chemosensitivity of HCC cells to DDP by inhibiting the STAT3/PTTG1 pathway.
format Online
Article
Text
id pubmed-8138572
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81385722021-05-22 Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway Hong, Han Jin, Zhengkang Qian, Tao Xu, Xiaoyong Zhu, Xiang Fei, Qiang Yang, Jiamei Sui, Chengjun Xu, Minhui Front Pharmacol Pharmacology Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy globally and the third leading cause of cancer-related death. Chemotherapy is one of the main methods in treating HCC, while recent studies have found that the resistance of HCC to chemotherapeutic drugs reduces the efficacy of the chemotherapy. Falcarindiol (FAD) is a cytotoxic and anti-inflammatory polyacetylenic oxylipin found in food plants of the carrot family (Apiaceae), while its role in HCC remains to be explored. Here, HCC cells (Huh7 and LM3) were treated with FAD at different doses. Cell proliferation was tested by the cell counting kit-8 (CCK-8) method and colony formation assay, while the apoptosis was monitored by flow cytometry. The profiles of apoptosis-related proteins (Bax, bcl2, and Caspase-3), DNA repair proteins (Rad51, BRCA1, and MDC1), and the signal transducer and activator of transcription 3 (STAT3)/Pituitary Tumor Transforming Gene 1 (PTTG1) were verified by western blot (WB) or quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The interaction between STAT3 and PTTG1 was verified by immunoprecipitation (IP). In addition, a xenograft tumor model was constructed in mice to explore the anti-tumor effects of FAD in vivo, and immunohistochemistry (IHC) was performed to count the number of Ki67-stained cells. As a result, FAD inhibited HCC cell proliferation and DNA repair, facilitated their apoptosis, and also enhanced cisplatin (DDP) chemosensitivity. The Combination Index (CI) evaluation showed that FAD and DDP had synergistic effects in repressing HCC cell proliferation. Besides, FAD dampened the STAT3/PTTG1 pathway expression. Further studies revealed that inhibiting STAT3 enhanced the inhibitive effect of FAD on HCC cells, whereas overexpressing PTTG1 attenuated the anti-tumor effect of FAD. Overall, our study illustrated that FAD is a potential anticancer drug and strengthens the chemosensitivity of HCC cells to DDP by inhibiting the STAT3/PTTG1 pathway. Frontiers Media S.A. 2021-05-07 /pmc/articles/PMC8138572/ /pubmed/34025420 http://dx.doi.org/10.3389/fphar.2021.656697 Text en Copyright © 2021 Hong, Jin, Qian, Xu, Zhu, Fei, Yang, Sui and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hong, Han
Jin, Zhengkang
Qian, Tao
Xu, Xiaoyong
Zhu, Xiang
Fei, Qiang
Yang, Jiamei
Sui, Chengjun
Xu, Minhui
Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title_full Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title_fullStr Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title_full_unstemmed Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title_short Falcarindiol Enhances Cisplatin Chemosensitivity of Hepatocellular Carcinoma via Down-Regulating the STAT3-Modulated PTTG1 Pathway
title_sort falcarindiol enhances cisplatin chemosensitivity of hepatocellular carcinoma via down-regulating the stat3-modulated pttg1 pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138572/
https://www.ncbi.nlm.nih.gov/pubmed/34025420
http://dx.doi.org/10.3389/fphar.2021.656697
work_keys_str_mv AT honghan falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT jinzhengkang falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT qiantao falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT xuxiaoyong falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT zhuxiang falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT feiqiang falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT yangjiamei falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT suichengjun falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway
AT xuminhui falcarindiolenhancescisplatinchemosensitivityofhepatocellularcarcinomaviadownregulatingthestat3modulatedpttg1pathway